Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Kassondra S GrzankowskiPeter J Frederick

Abstract

The time interval between diagnoses of breast cancer (BC) and endometrial cancer (EC) is not well established in women with metachronous primary tumors. We sought to examine this interval and identify associations with treatment-related and clinicopathologic factors. We identified 141 patients who developed both cancers during 1966 to 2013. Patients were divided into 2 groups: group 1, BC first, and group 2, EC first. Subanalysis performed of group 1 (59 patients) stratified around adjuvant tamoxifen use: pre-1990 BC diagnosis and post. Fifty-nine and 82 patients were in groups 1 and 2, respectively. The mean time interval was comparable (76 vs 74 months, P = 0.861). Subanalysis divided group 1 into pre- (n = 27) and post- (n = 32) 1990 and resulted in different mean time intervals between diagnosis of metachronous cancers (106 vs 50 months, respectively [P = 0.042]). Median progression-free survival (PFS) and overall survival (OS) for EC were longer in the pre group (PFS, 51 vs 26 months [P = 0.169]; OS, 59 vs 27 months [P = 0.190]). Median PFS and OS for BC were also longer in this group (PFS, 147 vs 109 months [P = 0.005]; OS, 166 vs 114 months [P < 0.001]). Our data indicate the mean time interval between the diagnosis of E...Continue Reading

References

Nov 5, 1994·Lancet·D BissettW D George
Sep 30, 1994·Annals of the New York Academy of Sciences·P SismondiT de Grandis
Jun 1, 1996·Cancer·E B ClausN J Risch
Oct 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H F VasenJ T Wijnen
May 25, 2002·The New England Journal of Medicine·Timothy R RebbeckUNKNOWN Prevention and Observation of Surgical End Points Study Group
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry T LynchWendy S Rubinstein
Nov 19, 2005·Nature Reviews. Cancer·James M Allan, Lois B Travis
Dec 15, 2005·Gynecologic Oncology·Sarah E FergusonRichard R Barakat
Jan 5, 2006·Journal of the National Cancer Institute·Lois B TravisMark H Greene
Oct 24, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lois B Travis
Oct 22, 2008·Gynecologic Oncology·Amy E BlandLaura Havrilesky
Dec 9, 2008·The Cancer Journal·Andrea K Ng, Lois B Travis
Dec 5, 2009·Seminars in Radiation Oncology·Andrea K NgLois B Travis
Aug 1, 2012·The Cancer Journal·Molly S Daniels
Oct 19, 2013·Oncology Letters·Tonya M Martin-DunlapJulie A Margenthaler
Feb 27, 2014·Menopause : the Journal of the North American Menopause Society·Risa MaruokaMasahide Ohmichi
Sep 23, 2014·Gynecologic Oncology·Johnathan M LancasterUNKNOWN SGO Clinical Practice Committee

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.